Four professionals from Primary Care Family and Community Medicine at the Lanzarote Health Area, affiliated with the Canary Islands Government's Health Department, have published a scientific paper in the journal ‘Medicina de Familia. SEMERGEN’. The study analyzes new perspectives in managing dyslipidemia, particularly the role of PCSK9 inhibitors in patients with high cardiovascular risk.
The publication, authored by Family Medicine specialists Yulene Larrañaga and María Yanes, along with residents Susana Espinosa and Carla Betancor, showcases the research activity of professionals at the Lanzarote Health Services Management and their commitment to continuous training and knowledge updates to improve the prevention and healthcare of cardiovascular diseases.
The work reviews available scientific evidence on new therapeutic alternatives for controlling LDL cholesterol, a major risk factor for cardiovascular diseases. The authors highlight the evolution of treatment strategies and the role of PCSK9 inhibitors, especially indicated for patients with high or very high cardiovascular risk who do not achieve their cholesterol targets with conventional treatments.
These treatments represent one of the most significant therapeutic advances in recent decades for managing dyslipidemia, enabling substantial and sustained reductions in LDL cholesterol and decreasing the risk of major cardiovascular events, particularly in high-risk individuals.
The article emphasizes that the incorporation of new treatments does not replace basic prevention measures, underscoring the importance of maintaining healthy lifestyle habits.
The authors highlight the essential role of Primary Care professionals in the early detection of patients with cardiovascular disease, familial hypercholesterolemia, very high LDL cholesterol levels, diabetes with organ involvement, or advanced kidney disease. This allows for more intensive prevention strategies without waiting for a cardiovascular event and for subsequent follow-up.
The study concludes that PCSK9 inhibitors are a valuable therapeutic tool for patients at cardiovascular risk, as part of a comprehensive strategy that combines pharmacological treatment, risk factor control, and the promotion of healthy lifestyles.
The publication of this study underscores the role of Primary Care not only in the prevention, detection, and monitoring of cardiovascular risk factors but also in the generation and dissemination of scientific knowledge.
The Primary Care Directorate of the Lanzarote Health Area commends the work of these professionals, acknowledging their contribution to updating knowledge on this medically significant pathology and to disseminating new therapeutic tools among healthcare professionals.
